XTL Biopharma seeks Nasdaq trading stay after staff delist determination letter

XTL Biopharmaceuticals Ltd. Sponsored ADR

XTLB

0.00

XTL Biopharmaceuticals received a Nasdaq staff delist determination dated May 18, 2026, citing the company’s failure to file its annual report for the year ended Dec. 31, 2025.
The filing lapse adds to an ongoing delisting review tied to noncompliance with Nasdaq’s minimum stockholders’ equity threshold of $2.5 million and the $1 bid-price requirement.
The company plans to seek an extended stay of any suspension by May 26, 2026, pending a hearings panel decision.
Nasdaq set May 26, 2026 as the deadline for XTL to submit its written response on the added deficiency to the panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605221610PRIMZONEFULLFEED9725486) on May 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.